Cellectis S.A.
CLLS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001627281
No open-market purchases or sales by Cellectis S.A. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $28.4M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −5 vs. previous quarter
- 27
- 13F valueReported value at the end of Q2 2026
- $28.4M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CLLS, Q2 2026
No superinvestor reported holding CLLS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Cellectis S.A. insiders from Form 4, newest first.
No open-market purchases or sales by Cellectis S.A. insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in Cellectis S.A. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| B Group, Inc. | 3,281,501 | $9.84M | 5.59% | 00.0% | Unchanged |
| Long Focus Capital Management, LLC | 2,741,853 | $8.23M | 0.34% | −2,245−0.1% | Reduced |
| UBS Asset Management Americas Inc | 2,644,881 | $7.93M | 0.00% | −533,739−16.8% | Reduced |
| Nomura Asset Management International Inc. | 226,875 | $681.0K | 0.00% | 00.0% | Unchanged |
| BlackRock, Inc. | 225,444 | $676.3K | 0.00% | −116,079−34.0% | Reduced |
| Morgan Stanley | 85,455 | $256.4K | 0.00% | −1,321−1.5% | Reduced |
| LPL Financial LLC | 84,415 | $253.2K | 0.00% | +70+0.1% | Added |
| Susquehanna International Group, LLP | 50,453 | $151.4K | 0.00% | −15,489−23.5% | Reduced |
| BNP Paribas Arbitrage, SA | 40,100 | $120.3K | 0.00% | −900−2.2% | Reduced |
| UBS Group AG | 33,926 | $101.8K | 0.00% | +4,152+13.9% | Added |